Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Drug Discov Today. 2018 Sep;23(9):1622-1634. doi: 10.1016/j.drudis.2018.06.015. Epub 2018 Jun 21.

U-BIOPRED: evaluation of the value of a public-private partnership to industry.

Author information

1
GlaxoSmithKline, Respiratory Therapy Area, Gunnels Wood Road, Stevenage, UK. Electronic address: john.h.riley@gsk.com.
2
Novartis Pharma AG, Basel, Switzerland.
3
Genentech Inc., South San Francisco, CA, USA.
4
GlaxoSmithKline, Respiratory Franchise, Brentford, UK.
5
Boehringer Ingelheim Pharma, GmbH & Co. KG, Biberach, Germany.
6
Allergy Therapeutics, Research and Development, Worthing, UK.
7
BioSci Consulting, Rijksweg, Belgium.
8
Jansen Pharmaceuticals, Johnson and Johnson, Philadelphia, PA, USA.
9
GlaxoSmithKline, Respiratory Therapy Area, Gunnels Wood Road, Stevenage, UK.

Abstract

Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) was initiated in the first year of the Innovative Medicines Initiative (IMI). It was an ambitious plan to tackle the understanding of asthma through an integration of clinical and multi-'omics approaches that necessitated the bringing together of industry, academic, and patient representatives because it was too large to be managed by any one of the partners in isolation. It was a novel experience for all concerned. In this review, we describe the main features of the U-BIOPRED experience from the industry perspective. We list some of the key advantages and learnings from the perspective of the authors, and also improvements that we feel could be made in future projects.

PMID:
29936248
DOI:
10.1016/j.drudis.2018.06.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center